Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
Background: This phase II, open-label study investigated intercalated combinations of eribulin and erlotinib in unselected patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapies. Patients and methods: Eligible patients were randomized to eribulin mesy...
Saved in:
Main Authors: | Tony S. Mok, S. L. Geater, N. Iannotti, S. Thongprasert, A. Spira, D. Smith, V. Lee, W. T. Lim, L. Reyderman, B. Wang, P. Gopalakrishna, F. Garzon, L. Xu, C. Reynolds |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84905162106&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/53863 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
by: Tony S. Mok, et al.
Published: (2018) -
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
by: Mok T.S., et al.
Published: (2014) -
Erlotinib in previously treated non-small-cell lung cancer
by: Frances A. Shepherd, et al.
Published: (2018) -
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
by: Scagliotti G.V., et al.
Published: (2014) -
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)